178 related articles for article (PubMed ID: 38321065)
1. Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient.
Lien SC; Ly D; Yang SYC; Wang BX; Clouthier DL; St Paul M; Gadalla R; Noamani B; Garcia-Batres CR; Boross-Harmer S; Bedard PL; Pugh TJ; Spreafico A; Hirano N; Razak ARA; Ohashi PS
Nat Commun; 2024 Feb; 15(1):1094. PubMed ID: 38321065
[TBL] [Abstract][Full Text] [Related]
2. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.
Church C; Pulliam T; Longino N; Park SY; Smythe KS; Makarov V; Riaz N; Jing L; Amezquita R; Campbell JS; Gottardo R; Pierce RH; Choi J; Chan TA; Koelle DM; Nghiem P
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36252564
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas.
Donizy P; Wu CL; Kopczynski J; Pieniazek M; Biecek P; Ryś J; Hoang MP
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071045
[TBL] [Abstract][Full Text] [Related]
5. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.
Afanasiev OK; Yelistratova L; Miller N; Nagase K; Paulson K; Iyer JG; Ibrani D; Koelle DM; Nghiem P
Clin Cancer Res; 2013 Oct; 19(19):5351-60. PubMed ID: 23922299
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling.
Martins C; Rasbach E; Heppt MV; Singh P; Kulcsar Z; Holzgruber J; Chakraborty A; Mucciarone K; Kleffel S; Brandenburg A; Hoetzenecker W; Rahbari NN; DeCaprio JA; Thakuria M; Murphy GF; Ramsey MR; Posch C; Barthel SR; Schatton T
Sci Adv; 2024 Jan; 10(3):eadi2012. PubMed ID: 38241371
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
8. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
Mitteldorf C; Berisha A; Tronnier M; Pfaltz MC; Kempf W
J Cutan Pathol; 2017 Sep; 44(9):740-746. PubMed ID: 28569410
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses.
Dowlatshahi M; Huang V; Gehad AE; Jiang Y; Calarese A; Teague JE; Dorosario AA; Cheng J; Nghiem P; Schanbacher CF; Thakuria M; Schmults CD; Wang LC; Clark RA
J Invest Dermatol; 2013 Jul; 133(7):1879-89. PubMed ID: 23419694
[TBL] [Abstract][Full Text] [Related]
10. Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.
Giraldo NA; Nguyen P; Engle EL; Kaunitz GJ; Cottrell TR; Berry S; Green B; Soni A; Cuda JD; Stein JE; Sunshine JC; Succaria F; Xu H; Ogurtsova A; Danilova L; Church CD; Miller NJ; Fling S; Lundgren L; Ramchurren N; Yearley JH; Lipson EJ; Cheever M; Anders RA; Nghiem PT; Topalian SL; Taube JM
J Immunother Cancer; 2018 Oct; 6(1):99. PubMed ID: 30285852
[TBL] [Abstract][Full Text] [Related]
11. Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma.
Bénigni P; Guénolé M; Bonsang B; Marcorelles P; Schick U; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):17-22. PubMed ID: 31343994
[TBL] [Abstract][Full Text] [Related]
12. Merkel cell carcinomas infiltrated with CD33
Kervarrec T; Gaboriaud P; Berthon P; Zaragoza J; Schrama D; Houben R; Le Corre Y; Hainaut-Wierzbicka E; Aubin F; Bens G; Domenech J; Guyétant S; Touzé A; Samimi M
J Am Acad Dermatol; 2018 May; 78(5):973-982.e8. PubMed ID: 29273486
[TBL] [Abstract][Full Text] [Related]
13. γδ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival.
Gherardin NA; Waldeck K; Caneborg A; Martelotto LG; Balachander S; Zethoven M; Petrone PM; Pattison A; Wilmott JS; Quiñones-Parra SM; Rossello F; Posner A; Wong A; Weppler AM; Shannon KF; Hong A; Ferguson PM; Jakrot V; Raleigh J; Hatzimihalis A; Neeson PJ; Deleso P; Johnston M; Chua M; Becker JC; Sandhu S; McArthur GA; Gill AJ; Scolyer RA; Hicks RJ; Godfrey DI; Tothill RW
Cancer Immunol Res; 2021 Jun; 9(6):612-623. PubMed ID: 33674358
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade.
Tabachnick-Cherny S; Pulliam T; Rodriguez HJ; Fan X; Hippe DS; Jones DC; Moshiri AS; Smythe KS; Kulikauskas RM; Zaba LC; Paulson KG; Nghiem P
Clin Cancer Res; 2024 Mar; 30(6):1189-1199. PubMed ID: 37851052
[TBL] [Abstract][Full Text] [Related]
15. Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma.
Pulliam T; Jani S; Jing L; Ryu H; Jojic A; Shasha C; Zhang J; Kulikauskas R; Church C; Garnett-Benson C; Gooley T; Chapuis A; Paulson K; Smith KN; Pardoll DM; Newell EW; Koelle DM; Topalian SL; Nghiem P
Cell Rep Med; 2024 Feb; 5(2):101412. PubMed ID: 38340723
[TBL] [Abstract][Full Text] [Related]
16. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract][Full Text] [Related]
17. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.
Feldmeyer L; Hudgens CW; Ray-Lyons G; Nagarajan P; Aung PP; Curry JL; Torres-Cabala CA; Mino B; Rodriguez-Canales J; Reuben A; Chen PL; Ko JS; Billings SD; Bassett RL; Wistuba II; Cooper ZA; Prieto VG; Wargo JA; Tetzlaff MT
Clin Cancer Res; 2016 Nov; 22(22):5553-5563. PubMed ID: 27166398
[TBL] [Abstract][Full Text] [Related]
18. Concurrent High PD-L1 Expression and CD8
Shimoda Y; Shibaki R; Yoshida T; Murakami S; Shirasawa M; Torasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y; Motoi N
Clin Lung Cancer; 2022 Sep; 23(6):477-486. PubMed ID: 35644780
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
Spassova I; Ugurel S; Kubat L; Zimmer L; Terheyden P; Mohr A; Björn Andtback H; Villabona L; Leiter U; Eigentler T; Loquai C; Hassel JC; Gambichler T; Haferkamp S; Mohr P; Pfoehler C; Heinzerling L; Gutzmer R; Utikal JS; Horny K; Schildhaus HU; Habermann D; Hoffmann D; Schadendorf D; Becker JC
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074902
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of the expression of FOXP3 and TIGIT in Merkel cell carcinoma.
Iwasaki T; Hayashi K; Matsushita M; Nonaka D; Matsumoto T; Taniguchi M; Kuwamoto S; Umekita Y; Oda Y
Sci Rep; 2023 Aug; 13(1):13114. PubMed ID: 37573372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
